Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

Free Radical Biology and Medicine

Volumn 49, Issue 11, 2010, Pages 1674-1684

  Ghosh, Anamitra ^a   Chandran, Karunakaran ^b   Kalivendi, Shasi V ^b   Joseph, Joy ^b   Antholine, William E ^b   Hillard, Cecilia J ^b   Kanthasamy, Arthi ^a   Kanthasamy, Anumantha ^a   Kalyanaraman, Balaraman ^b  

^a IOWA STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Co Q; Free radicals; Mito Q10; MPP+; MPTP; Oxidants; Oxidative stress; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACONITATE HYDRATASE; ANTIOXIDANT; BETA ACTIN; CASPASE 3; MITO Q10; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE; UBIDECARENONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME INACTIVATION; LOCOMOTION; MALE; MEMBRANE POTENTIAL; MESENCEPHALON; METABOLITE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CELLS, CULTURED; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; ORGANOPHOSPHORUS COMPOUNDS; OSMOLAR CONCENTRATION; PARKINSONIAN DISORDERS; RATS; UBIQUINONE;

MUS; VASCONCELLEA CANDICANS;

EID: 78049357951     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.08.028     Document Type: Article

References (64)

1. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 1983, 80:4546-4550.
2. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
3. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-723.
4. Fahn S., Przedborski S. Parkinsonism. Merritt's Neurology 2002, 679-695. Lippincott, Williams & Wilkins, New York. L.P. Rowland (Ed.).
5. Greenamyre J.T., Betarbet R., Sherer T., Panov A. Parkinson's disease, pesticides and mitochondrial function. Trends Neurosci. 2001, 24:247.
6. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141-151.
7. Mizuno Y., Susuki K., Sone N., Saitoh T. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mouse brain in vivo. Neurosci. Lett. 1988, 91:349-353.
8. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983, 219:979-980.
9. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res. 1979, 1:249-254.
10. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: neuropathologic considerations. Adv. Neurol. 1993, 60:600-608.
11. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyrine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
12. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 2002, 22:7006-7015.
13. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 1984, 120:574-578.
14. Ramsay R.R., Kowa A.T., Johnson M.K., Salach J.I., Singer T.P. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, is near the Q-binding site of NADH dehydrogenase. Arch. Biochem. Biophys. 1987, 259:645-649.
15. Bates T.E., Heales S.J., Davies S.E., Boakye P., Clark J.B. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. J. Neurochem. 1994, 63:640-648.
16. Schapira A.H., Cooper V.J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
17. Schapira A.H.V. Mitochondrial disease. Lancet 2006, 368:70-82.
18. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 2001, 108:1263-1282.
19. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: implications for Parkinson's disease. J. Biol. Chem. 2000, 275:26096-26101.
20. Lin M.T., Beal F.M. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-802.
21. Schon E.A., Manfredi G. Neurodeneration and mitochondrial dysfunction. J. Clin. Invest. 2003, 111:303-312.
22. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
23. Götz M.E., Künig G., Riederer P., Youdim M.B. Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 1994, 63:37-122.
24. Qian Z.M., Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res. Rev. 1998, 27:257-267.
25. Golden T.R., Patel M. Catalytic antioxidants and neurodegeneration. Antioxid. Redox Signaling 2009, 11:555-570.
26. Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology 2006, 66(10 Suppl. 4):S50-S57.
27. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Anderson J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
28. Dhanasekaran A., Kotamraju S., Kalivendi S.V., Matsunaga T., Shang T., Keszler A., Joseph J., Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem. 2004, 279:37575-37587.
29. Murphy M.P. Selective targeting of bioactive compounds to mitochondria in vivo. Trends Biotechnol. 1997, 15:326-330.
30. Kelso G.F., Porteous C.M., Hughes G., Ledgerwood E.C., Gane A.M., Smith R.A., Murphy M.P. Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann. NY Acad. Sci. 2002, 959:263-274.
31. Cheung N.S., Hickling Y.M., Beart P.M. Development and survival of rat embryonic mesencephalic dopaminergic neurones in serum-free, antioxidant-rich primary cultures. Neurosci. Lett. 1997, 233:13-16.
32. Dreschel D.A., Liang L.P., Patel M. 1-Methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicol. Appl. Pharmacol. 2007, 220:341-348.
33. Zhang D., Anantharam V., Kanthasamy A., Kanthasamy A.G. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007, 322:913-922.
34. +)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur. J. Neurosci. 2003, 18:1387-1401.
35. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase: effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 2001, 276:47266-47276.
36. +-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 2004, 279:15240-15247.
37. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., Ghosh S., Mosley R.L., Gendelman H.E., Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2007, 104:18754-18759.
38. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2004, 101:9435-9440.
39. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H.E., Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2009, 29:13543-13556.
40. Dessolin J., Schuler M., Quinart A., De Giorgi F., Ghosez L., Ichas F. Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases?. Eur. J. Pharmacol. 2002, 447:155-161.
41. Chandran K., Aggarwal D., Migrino R.Q., Joseph J., McAllister D., Konorev E.A., Antholine W.E., Zielonka J., Srinivasan S., Avadhani N.G., Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys. J. 2009, 96:1388-1398.
42. Adams F.S., La Rosa F.G., Kumar S., Edwards-Prasad J., Kentroti S., Vernadakis A., Freed C.R., Prasad K.N. Characterization and transplantation of two neuronal cell lines with dopaminergic properties. Neurochem. Res. 1996, 21:619-627.
43. Clarkson E.D., La Rosa F.G., Edwards-Prasad J., Weiland D.A., Witta S.E., Freed C.R., Prasad K.N. Improvement of neurological deficits in 6-hydroxydopamine-lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells. Proc. Natl Acad. Sci. USA 1998, 95:1265-1270.
44. Doughan A.K., Dikalov S.I. Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid. Redox Signaling 2007, 9:1825-1836.
45. Vásquez-Vivar J., Kalyanaraman B., Kennedy M.C. Mitochondrial aconitase as a source of hydroxyl radical: an electron spin resonance investigation. J. Biol. Chem. 2000, 275:14064-14069.
46. Liang L.P., Patel M. Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. J. Neurochem. 2003, 90:1076-1084.
47. Gerlach M., Riederer P., Przuntek H., Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 1991, 208:273-286.
48. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T., Greenamyre J.T. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 2005, 280:42026-42035.
49. Shults C.W., Haas R.H., Passov D., Beal M.F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 1997, 42:261-264.
50. Lovenberg W., Levine R.A., Robinson D.S., Ebert M., Williams A.C., Calne D.B. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science 1979, 204:624-626.
51. Przedborski S. Peroxiredoxin-2 links Cdk5 to neurodegeneration. Nat. Med. 2007, 13:907-909.
52. Smith R.A.J., Porteous C.M., Coulter C.V., Murphy M.P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem. 1999, 263:709-716.
53. Smith R.A.J., Porteous C.M., Gane A.M., Murphy M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl Acad. Sci. USA 2003, 100:5407-5412.
54. Jauslin M.L., Meier T., Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003, 17:1972-1974.
55. James A.M., Cochemé H.M., Smith R.A., Murphy M.P. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species: implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem. 2005, 280:21295-21312.
56. Murphy M.P., Smith R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 2007, 47:629-656.
57. James A.M., Sharpley M.S., Manas A.-R.B., Frerman F.E., Hirst J., Smith R.A.J., Murphy M.P. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem. 2007, 282:14708-14718.
58. Schwartz J.H., Tattersall I. Significance of some previously unrecognized apomorphies in the nasal region of Homo neanderthalensis. Proc. Natl Acad. Sci. USA 1996, 93:10852-10854.
59. Kühn K., Wellen J., Link N., Maskri L., Lübbert H., Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 2003, 17:1-12.
60. Snow B.J., Rolfe F.L., Murphy M.P., Smith R.A., Lockhart M.M., Frampton C.M., Taylor K.M. Phase II study of the mitochondrial antioxidant mitoquinone for Parkinson's disease. Neurology 2008, 70:A483-A484.
61. Gane E.J., Orr D.W., Weilert F., Keogh G.F., Gibson M., Murphy M.P., Smith R.A.J., Lockhart M.M., Frampton C.M., Taylor K.M. Phase II study of the mitochondrial antioxidant mitoquinone for hepatitis C. J. Hepatol. 2008, 48:S318.
62. 10. BMC Neurosci. 2009, 10:88.
63. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA 2007, 104:1320-1325.
64. Lu Z.H., Fleming S.M., Meurers B., Ackerson L.C., Mortazavi F., Lo V., Hernandez D., Sulzer D., Jackson G.R., Maidment N.T., Chesselet M.F., Yang X.W. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant α-synuclein. J. Neurosci. 2009, 29:1962-1976.